Zhang L,Wang F,Wang L,et al. Prevalence of chronic kidney disease in China:a cross-sectional survey [J]. Lancet,2012,379(9818):815.
[2]
Razzaque M S,Taguchi T. Cellular and molecular events leading to renal tubulointerstitial fibrosis [J]. Med Electron Microsc,2002,35(2):68.
[3]
Abrass C K,Adcox M J,Raugi G J. Aging-associated changes in renal extracellular matrix [J]. Am J Pathol,1995,146(3):742.
[4]
Urushihara M,Kagami S,Kuhara T,et al. Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis [J]. Nephrol Dial Transplant,2002,17(7):1189.
[5]
Ahuja T S,Gopalani A,Davies P,et al. Matrix metalloproteinase-9 expression in renal biopsies of patients with HIV-associated nephropathy [J]. Nephron Clin Pract,2003,95(3):c100.
[6]
Bauvois B,Mothu N,Nguyen J,et al. Specific changes in plasma concentrations of matrix metalloprotei-nase-2 and -9,TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis [J]. Nephrol Dial Transplant,2007,22(4):1115.
[7]
Czech K A,Bennett M,Devarajan P. Distinct metalloproteinase excre-tion patterns in focal segmental glomerulosclerosis [J]. Pediatr Nephrol,2011,26(12):2179.
[8]
Sanders J S,van Goor H,Hanemaaijer R,et al. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis [J]. Nephrol Dial Transplant,2004,19(6): 1412.
[9]
Aoyama T,Yamamoto S,Kanematsu A,et al. Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice [J]. Tissue Eng,2003,9(6):1289.
[10]
Tveita A,Rekvig O P,Zykova S N. Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis [J]. Arthritis Res Ther,2008,10(6):229.
[11]
Mitani O,Katoh M,Shigematsu H. Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis [J]. Pathol Int,2004,54(4):241.
[12]
Tomita M,Koike H,Han G D,et al. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion [J].Clin Exp Nephro,2004,8(1):17.
[13]
Derynck R,Zhang Y E. Smad-dependent and Smad-independent pathways in TGF-beta family signaling [J]. Nature,2003,425(6958):577.
[14]
Phanish M K,Wahab N A,Colville-Nash P,et al. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGF-beta1 responses in human proximal-tubule epithelial cells [J]. Biochem J,2006,393(Pt 2):601.
Iimura O,Takahashi H,Yashiro T,et al. Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex [J]. Clin Exp Nephrol,2004,8(3):223.
[22]
Cheng S,Lovett D H. Gelatinase A(MMP-2)is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation [J]. Am J Pathol,2003,162(6):1937.
Li J,Kang S W,Kim J L,et al. Isoliquiritigenin entails blockade of TGF-beta1-SMAD signaling for retarding high glucose-induced mesangial matrix accumulation [J]. J Agric Food Chem,2010,58(5):3205.
[26]
吴以岭. 脉络论[M]. 北京:中国科学技术出版社,2010:927.
[27]
Rerolle J P,Hertig A,Nguyen G. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis [J]. Kidney Int,2000,58(5):1841.
[28]
Sibalic V,Sun L,Sibalic A,et al. Characteristic matrix and tubular basement membrane abnormalities in the CBA/Ca-kdkd mouse model of hereditary tubulointerstitial disease [J]. Nephron,1998,80(3):305.
[29]
Baricos W H,Cortez S L,el-Dahr S S,et al. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade [J]. Kidney Int,1995,47(4):1039.
[30]
Woessner J F Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling [J]. FASEB J,1991,5(8):2145.
[31]
Catania J M,Chen G,Parrish A R. Role of matrix metalloproteinases in renal pathophysiologies [J]. Am J Physiol Renal Physiol,2007,292(3):F906.
[32]
Johnson L L,Dyer R,Hupe D J. Matrix metalloproteinases [J]. Curr Opin Chem Biol,1998,2(4):466.
[33]
Schutte J,Viallet J,Nau M,et al. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun [J]. Cell,1989,59(6):987.
[34]
Tanaka H,Terada Y,Kobayashi T,et al. Expression and function of Ets-1 during experimental acute renal failure in rats [J]. J Am Soc Nephrol,2004,15(12):3083.
[35]
Reisdorff J,En-Nia A,Stefanidis I,et al. Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells [J]. J Am Soc Nephrol,2002,13(6):1568.
[36]
Mignatti P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators [J]. Kidney Int Suppl 1995,49:S12.
[37]
Oikawa T,Freeman M,Lo W,et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition [J]. Kidney Int,1997,51(1):164.
Naito T,Tanihata Y,Nishimura H,et al. Expression of matrix metalloproteinase-9 associated with ets-1 proto-oncogene in rat tubulointerstitial cells [J]. Nephrol Dial Transplant,2005,20(11):2333.
[45]
Singh R,Song R H,Alavi N,et al. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1 [J]. Exp Nephrol,2001,9(4):249.
